Format

Send to

Choose Destination
Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e85-e93. doi: 10.1016/j.clml.2017.11.004. Epub 2017 Dec 6.

Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma.

Author information

1
Department of Dermatology, Yale University School of Medicine, New Haven, CT. Electronic address: benoit.cyrenne@yale.edu.
2
Department of Dermatology, Yale University School of Medicine, New Haven, CT.
3
Department of Dermatology and Pathology, Yale University School of Medicine, New Haven, CT.
4
Hematology and Bone Marrow Transplantation, Yale University School of Medicine, New Haven, CT.

Abstract

BACKGROUND:

Primary cutaneous aggressive epidermotropic cytotoxic CD8 positive T-cell lymphoma (CD8+ PCAETL) is a rare subtype of peripheral T-cell lymphoma with poor outcomes and without a standardized treatment strategy. Allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested as a potential curative therapy.

PATIENTS AND METHODS:

We conducted a retrospective case series. We identified 8 patients with the diagnosis of CD8+ PCAETL, 4 of whom also underwent allogeneic HSCT.

RESULTS:

Eight patients were treated at our center with combination chemotherapy and several novel agents, including histone deacetylase inhibitors, brentuximab, and pralatrexate. Patients underwent a median of 8.5 treatments before HSCT. Six of the 8 patients examined, including all 4 who received an HSCT, were alive at their last follow-up.

CONCLUSION:

Allogeneic HSCT is a promising treatment modality for CD8+ PCAETL. Because of the aggressive nature of this disease and lack of sustained remission with currently available therapies, HSCT should be considered early in the course of treatment. Two novel agents, brentuximab and pralatrexate, showed significant activity against CD8+ PCAETL, and may be incorporated earlier in the treatment course.

KEYWORDS:

Algorithms; CD8(+) PCAETL; CTCL; Hematopoietic stem cell transplantation; Outcome; Response

PMID:
29223388
DOI:
10.1016/j.clml.2017.11.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center